Dr. Reddy’s: Lessons from Omeprazole - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Dr. Reddy’s: Lessons from Omeprazole

Nov 20, 2001

Yesterday, Dr. Reddy’s ADR was down by around 18% on the NYSE following withdrawal of tentative Omeprazole approval which seems to have worked as a major anti-climax for investors. Whether the fall was justified or the market overreacted to the news is a different story but the point here is investors need to understand the nature of generic business before investing. Apart from the company’s capability, what matters is the timing, patience, skills and financial muscle to fight legal battles. This is all the more true in case of Para IV applications. A Para IV application is one in which a generic company challenges a patented product to prove that the generic version can stand the same test of efficacy. Further, to get six months marketing exclusivity the company also needs to be the first to file this application.

Now, the cream for the original innovator of the drug is the period the drug remains under patent, as it charges a hefty premium for it innovation and monopoly. Off course, the innovator would try to prevent the entry of a generic product and to do so various legal provisions; loopholes and financial muscle are used as war tactics. It is after all this legal drama that the generic drug enters a regulated market. Now, one can understand the degree of uncertainty, which precedes and follows launch of a generic product.

Let us consider a recent Bristol Myers, BuSpar case to understand the complexities. BuSpar is Bristol Myers multi-million anti-anxiety drug. After its patent expiry, a lower court in the US gave the green signal for entry of two generic copycats (from Watson and Mylan). However, months after the lower court gave this decision, US Court of Appeals reversed the earlier decision stating the lower court had no power to order US FDA to overlook the patent and pave the way for generics.

To conclude, there is a big opportunity waiting for Indian generic companies who are geared to latch on to that market. However, the road ahead would not be smooth and there would be negative surprises along the way. It would be advisable for investors in domestic pharma companies not to build expectations and factor in growth numbers either from generics or from R&D potential till clear earnings visibility arises on that front.

  • Read on the latest Omeprazole development

  • Equitymaster requests your view! Post a comment on "Dr. Reddy’s: Lessons from Omeprazole". Click here!


    More Views on News

    DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

    Feb 4, 2019 | Updated on Feb 4, 2019

    For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

    More Views on News

    Most Popular

    Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

    Sep 17, 2020

    This leading household brand will profit big time in a post covid world.

    My Top Stock to Buy in this Market Selloff (Profit Hunter)

    Sep 22, 2020

    The recent correction offers a great opportunity to buy this high conviction smallcap stock.

    What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

    Sep 18, 2020

    Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

    How Much Money Do You Need to Be a Professional Trader? (Fast Profits Daily)

    Sep 17, 2020

    In this video I'll answer a question I get asked often: How much capital do I really need to trade the markets for a living? Let's find out...


    Covid-19 Proof
    Multibagger Stocks

    Covid19 Proof Multibaggers
    Get this special report, authored by Equitymaster's top analysts now!
    We will never sell or rent your email id.
    Please read our Terms


    Sep 25, 2020 (Close)


    • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks